Patient diagnosed with chronic erectile dysfunction refractory to PDE 5 Inhibitor therapy reports improvement in function after hyperbaric oxygen therapy.

What Researchers Did

Researchers described a case of a male patient with chronic erectile dysfunction refractory to standard therapy who received hyperbaric oxygen therapy.

What They Found

A male patient with Type 1 diabetes and chronic erectile dysfunction refractory to PDE5 inhibitors received 60 hyperbaric oxygen treatments over 15 weeks for a foot wound. He reported improved erectile function, including morning tumescence, after the first 20 treatments, which persisted 24 weeks after the final treatment.

What This Means for Canadian Patients

This case suggests that hyperbaric oxygen therapy might be a potential avenue for Canadian men experiencing chronic erectile dysfunction, especially those with diabetes and refractory to conventional treatments. However, patients should discuss all treatment options with their doctor, as this is only a single case report.

Canadian Relevance

This study has no direct Canadian connection as it was not conducted in Canada nor involved Canadian researchers or patients.

Study Limitations

As a single case report, these findings cannot be generalized to a broader patient population and require further investigation through larger studies.